Metsera, Inc.
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Metsera, Inc. and buy or sell other stocks, ETFs, and their options commission-free!About MTSR
Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
CEOChristopher Whitten Bernard, MBA
CEOChristopher Whitten Bernard, MBA
Employees81
Employees81
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded
Founded
Employees81
Employees81
MTSR Key Statistics
Market cap7.41B
Market cap7.41B
Price-Earnings ratio-23.55
Price-Earnings ratio-23.55
Dividend yield—
Dividend yield—
Average volume4.34M
Average volume4.34M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$83.86
52 Week high$83.86
52 Week low$12.30
52 Week low$12.30
Stock Snapshot
Metsera, Inc.(MTSR) stock is priced at $70.50, giving the company a market capitalization of 7.41B. It carries a P/E multiple of -23.55.
On 2026-01-14, Metsera, Inc.(MTSR) shares started trading at —, with intraday highs of — and lows of —.
Trading activity shows a volume of 0, compared to an average daily volume of 4.34M.
The stock's 52-week range extends from a low of $12.30 to a high of $83.86.
The stock's 52-week range extends from a low of $12.30 to a high of $83.86.
People also own
Based on the portfolios of people who own MTSR. This list is generated using Robinhood data, and it’s not a recommendation.